Antifibrinolytic Drugs Market Report 2026

Antifibrinolytic Drugs Market Overview

• Antifibrinolytic Drugs market size has reached to $17.84 billion in 2025 • Expected to grow to $23.54 billion in 2030 at a compound annual growth rate (CAGR) of 5.6% • Growth Driver: Surgical Procedures Propel Growth Of The Antifibrinolytic Drug Market • Market Trend: New Direct-to-Consumer Antifibrinolytic Drugs Revolutionize Women's Health Management • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Antifibrinolytic Drugs Market?

Antifibrinolytic drugs are medications that prevent the breakdown of blood clots by inhibiting enzymes such as plasmin, crucial for controlling excessive bleeding. These drugs are used to treat or prevent bleeding in conditions such as hemophilia, heavy menstrual bleeding, and during surgeries where significant blood loss is expected. The main indications in antifibrinolytic drugs are gynecology, hereditary angioedema, fibrinolytic response testing, surgeries, and others. Gynecology is the branch of medicine focused on the female reproductive system, and in the context of antifibrinolytic drugs, it involves using these medications to address bleeding issues associated with gynecological conditions or surgical procedures. These drugs are administered through various routes, such as injectable, oral, and topical methods. They are utilized by a range of end users, such as hospitals and clinics, ambulatory surgical centers, and trauma centers.

What Is The Antifibrinolytic Drugs Market Growth Forecast?

The antifibrinolytic drugs market size is expected to see strong growth in the next few years. It will grow to $23.54 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to increasing demand from ambulatory surgical centers, rising focus on patient blood management programs, expansion of emergency care infrastructure, growing use in orthopedic and cardiovascular surgeries, continued development of safer formulations. Major trends in the forecast period include increasing use of antifibrinolytics in surgical procedures, rising adoption in trauma and emergency care, expansion of oral and injectable formulations, growing focus on blood loss management, enhanced clinical protocol standardization.

Global Antifibrinolytic Drugs Market Segmentation

1) By Indication: Gynecology, Hereditary Angioedema, Fibrinolytic Response Testing, Surgeries, Other Indications 2) By Route Of Administration: Injectable, Oral, Topical 3) By End User: Hospitals And Clinics, Ambulatory Surgical Centers, Trauma Centers Subsegments: 1) By Gynecology: Menorrhagia (Heavy Menstrual Bleeding), Postpartum Hemorrhage, Endometriosis-Related Bleeding 2) By Hereditary Angioedema: Acute Attacks Of Hereditary Angioedema, Prophylaxis For Hereditary Angioedema 3) By Fibrinolytic Response Testing: Testing For Fibrinolysis Activity in Trauma, Cardiac Surgery Fibrinolytic Response Testing, Testing In Coagulation Disorders 4) By Surgeries: Orthopedic Surgeries, Cardiovascular Surgeries, Dental Surgeries, Neurosurgeries, Urological Surgeries 5) By Other Indications: Trauma and Injury-Related Bleeding, Post-Operative Bleeding Management, Hemophilia-Related Bleeding Control

What Is The Driver Of The Antifibrinolytic Drugs Market?

An increasing number of surgical procedures is expected to propel the growth of the antifibrinolytic drugs market going forward. Surgical procedures are rising due to several reasons, including advancements in medical technology, an aging population, increased awareness, and cultural and social factors. Antifibrinolytic drugs help reduce bleeding during surgery by preventing the breakdown of blood clots, leading to improved hemostasis and potentially decreasing the need for blood transfusions. For instance, in 2023, according to the International Society of Aesthetic Plastic Surgery, a US-based professional body of aesthetic plastic surgeons, total surgical and non-surgical procedures increased by 3.4% in 2023, up to 34.9 million. Therefore, the increasing number of surgical procedures is driving the growth of the antifibrinolytic drugs industry.

Key Players In The Global Antifibrinolytic Drugs Market

Major companies operating in the antifibrinolytic drugs market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Bayer AG, DAIICHI SANKYO COMPANY LIMITED, Sun Pharmaceutical Industries Ltd, Takeda Pharmaceuticals, Aurobindo Pharma Limited, Cipla Limited, Intas Pharmaceuticals, Lupin Limited, Zydus Lifesciences Ltd., Hetero Drugs Limited, Glenmark Pharmaceuticals, Alkem Laboratories, Torrent Pharmaceuticals Ltd, Macleods Pharmaceuticals Pvt Ltd, Mankind pharma Ltd, Emcure Pharmaceuticals ltd, Bharat Serums & Vaccines Ltd, Systopic Laboratories Pvt Ltd, Ozone Pharmaceuticals Ltd, ACIC Pharmaceuticals, AmeriGen Life Sciences LLP, Life Sciences Advanced Technologies Inc., Vitruvias Therapeutics Inc.

Global Antifibrinolytic Drugs Market Trends and Insights

Major companies operating in the antifibrinolytic drugs market are focusing on developing innovative solutions, such as the first-to-consumer approach, to provide easily accessible treatments for women suffering. The first-to-consumer approach refers to directly marketing these medications to patients rather than through traditional healthcare providers. For instance, in May 2024, Maxwellia Ltd., a UK-based healthcare company, launched two new pharmacy brands, Evana Heavy Period Relief 500 mg tablets and Ultravana Period Pain Relief 250 mg gastro-resistant tablets. Evana reduces heavy menstrual bleeding by up to 60%, while Ultravana offers effective relief for period pain; both are available without a prescription in UK pharmacies. Their significance lies in improving women's health by addressing common yet often neglected menstrual issues and empowering women to manage their symptoms more effectively.

What Are Latest Mergers And Acquisitions In The Antifibrinolytic Drugs Market?

In September 2025, A.forall, a Belgium-based developer and manufacturer of sterile injectable generics, acquired Provepharm’s U.S. generics portfolio for an undisclosed amount. Through this acquisition, A.forall aims to expand its hospital-use injectable business, including antifibrinolytic drugs such as tranexamic acid, and strengthen its presence in the U.S. generics market. Provepharm is a U.S.-based company that provides sterile injectable generics, including tranexamic acid.

Regional Insights

North America was the largest region in the antifibrinolytic drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Antifibrinolytic Drugs Market?

The antifibrinolytic drugs market consists of sales of tranexamic acid, aminocaproic acid, aprotinin, epsilon-aminocaproic acid, and desmopressin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Antifibrinolytic Drugs Market Report 2026?

The antifibrinolytic drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the antifibrinolytic drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.